Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 13/20 | 0.57 |
| ▸ | METTL3 | Q86U44 | 5/20 | 0.50 |
| ▸ | WDR77 | Q9BQA1 | 7/20 | 0.43 |
| ▸ | PI4KA | P42356 | 1/20 | 0.43 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.43 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.43 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.43 |
| ▸ | ADK | P55263 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22002033 | 1.00 | PRMT5 (0.57) | PRMT5METTL3WDR77PI4KAPI4K2B | |
| SCHEMBL22002170 | 0.90 | PRMT5 (0.45) | PRMT5METTL3WDR77PI4KAPI4K2B | |
| SCHEMBL22002128 | 0.86 | METTL3 (0.54) | PRMT5METTL3WDR77PI4KAPI4K2B | |
| SCHEMBL22002171 | 0.85 | PRMT5 (0.53) | PRMT5METTL3WDR77 | |
| SCHEMBL18572890 | 0.85 | METTL3 (0.59) | PRMT5METTL3WDR77 | |
| SCHEMBL22683095 | 0.85 | METTL3 (0.53) | PRMT5METTL3WDR77PI4KAPI4K2B | |
| SCHEMBL22002130 | 0.85 | METTL3 (0.53) | PRMT5METTL3WDR77PI4KAPI4K2B | |
| SCHEMBL23892638 | 0.84 | METTL3 (0.52) | PRMT5METTL3WDR77PI4KAPI4K2B | |
| SCHEMBL22002036 | 0.84 | METTL3 (0.52) | PRMT5METTL3WDR77PI4KAPI4K2B | |
| SCHEMBL18572317 | 0.84 | METTL3 (0.52) | PRMT5METTL3WDR77PI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10653711-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10653711-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | PRMT5, PRMT6, PRMT1 | PRMT5 1/4885METTL3 30/4885WDR77 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.